1. Musculoskeletal Partnering Terms and Agreements
Report Details:
Published:September 2012
No. of Pages: 1009
Price: Single User License – US$2695
This report provides comprehensive understanding and unprecedented access to the
musculoskeletal partnering deals and agreements entered into by the worlds leading healthcare
companies.
The report provides a detailed understanding and analysis of how and why companies enter
musculoskeletal partnering deals. The majority of deals are discovery or development stage
whereby the licensee obtains a right or an option right to license the licensors musculoskeletal
technology. These deals tend to be multicomponent, starting with collaborative R&D, and
commercialization of outcomes.
Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical
insight into the negotiation process in terms of what you can expect to achieve during the
negotiation of terms. Whilst many smaller companies will be seeking details of the payments
clauses, the devil is in the detail in terms of how payments are triggered – contract documents
provide this insight where press releases do not.
This report contains over 1,500 links to online copies of actual musculoskeletal deals and contract
documents as submitted to the Securities Exchange Commission by companies and their
partners. Contract documents provide the answers to numerous questions about a prospective
partner’s flexibility on a wide range of important issues, many of which will have a significant
impact on each party’s ability to derive value from the deal.
The initial chapters of this report provide an orientation of musculoskeletal dealmaking and
business activities. Chapter 1 provides an introduction to the report.
Chapter 2 provides an overview of the trends in musculoskeletal dealmaking since 2007 covering
trends by year, deal type, stage of development, technology type and therapeutic indication. In
addition the chapter includes an analysis of financial deal terms by stage at signing covering
headline value, upfront payment, milestone payments and royalty rates. Analysis includes median
values and distribution of values for each stage of development.
Chapter 3 provides a review of the leading musculoskeletal deals since 2007. Deals are listed by
headline value, signed by bigpharma, most active bigpharma, and most active of all biopharma
companies. Where the deal has an agreement contract published at the SEC a link provides
online access to the contract.
Chapter 4 provides a comprehensive listing of the top 50 bigpharma companies with a brief
summary followed by a comprehensive listing of musculoskeletal deals, as well as contract

2. documents available in the public domain. Where available, each deal title links via Weblink to an
online version of the actual contract document, providing easy access to each contract document
on demand.
Chapter 5 provides comprehensive access to all musculoskeletal deals since 2007 where a deal
contract is available, providing the user with direct access to contracts as filed with the SEC
regulatory authorities. Each deal title links via Weblink to an online version of the deal record
contract document, providing easy access to each contract document on demand.
Chapter 6 provides a comprehensive directory of all musculoskeletal partnering deals signed and
announced since 2007. The chapter is organized by specific musculoskeletal therapy focus. Each
deal title links via Weblink to an online version of the deal record and where available, the contract
document, providing easy access to each contract document on demand.
In addition, a comprehensive appendix is provided with each report of all musculoskeletal
partnering deals signed and announced since 2007. The appendices are organized by company
A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc)
and technology type. Each deal title links via Weblink to an online version of the deal record and
where available, the contract document, providing easy access to each contract document on
demand.
The report also includes numerous tables and figures that illustrate the trends and activities in
musculoskeletal partnering and dealmaking since 2007.
In conclusion, this report provides everything a prospective dealmaker needs to know about
partnering in the research, development and commercialization of musculoskeletal technologies
and products.
Musculoskeletal Partnering Terms and Agreements provides the reader with the following
key benefits:
•In-depth understanding of musculoskeletal deal trends since 2007
•Access musculoskeletal deal headline, upfront, milestone and royalty data
•Research hundreds of actual contracts between musculoskeletal partner companies
•Comprehensive access to over 1,500 links to actual musculoskeletal deals entered into by the
world’s biopharma companies
•Indepth review of musculoskeletal deals entered into by the leading fifty bigpharma companies
•Benchmark the key deal terms companies have agreed in previous deals
•Identify key terms under which companies partner musculoskeletal opportunities
•Uncover companies actively partnering musculoskeletal opportunities
Report scope
Musculoskeletal Partnering Terms and Agreements is intended to provide the reader with an in-
depth understanding and access to musculoskeletal trends and structure of deals entered into by
leading companies worldwide.
Musculoskeletal Partnering Terms and Agreements includes:
•Trends in musculoskeletal dealmaking in the biopharma industry since 2007
•Analysis of musculoskeletal deal structure
•Access to headline, upfront, milestone and royalty data

3. •Access to hundreds of musculoskeletal deal contract documents
•Comprehensive access to over 1,500 musculoskeletal deal records
•The leading musculoskeletal deals by value since 2007
•Most active musculoskeletal dealmakers since 2007
In Musculoskeletal Partnering Terms and Agreements, available deals and contracts are
listed by:
•Headline value
•Upfront payment value
•Royalty rate value
•Stage of development at signing
•Deal component type
•Technology type
•Specific therapy indication
Each deal title links via Weblink to an online version of the deal record and where available, the
contract document, providing easy access to each contract document on demand.
Get your copy of this report @
http://www.reportsnreports.com/reports/194242-musculoskeletal-partnering-terms-and-agreements.html
Major points covered in Table of Contents of this report include
Table of Contents
Executive Summary
Chapter 1 – Introduction
Chapter 2 – Trends in musculoskeletal dealmaking
2.1. Introduction
2.2. Musculoskeletal partnering over the years
2.3. Bigpharma musculoskeletal dealmaking activity
2.4. Bigpharma not active in musculoskeletal
2.5. Musculoskeletal partnering by deal type
2.6. Musculoskeletal partnering by industry sector
2.7. Musculoskeletal partnering by stage of development
2.8. Musculoskeletal partnering by technology type
2.9. Musculoskeletal partnering by musculoskeletal indication
2.10. Average deal terms for musculoskeletal
2.10.1 Musculoskeletal headline values
2.10.2 Musculoskeletal upfront payments
2.10.3 Musculoskeletal milestone payments
2.10.4 Musculoskeletal royalty rates
Chapter 3 – Leading musculoskeletal deals
3.1. Introduction
3.2. Top musculoskeletal deals by value
3.3. Top musculoskeletal deals involving bigpharma

4. Chapter 4 – Bigpharma musculoskeletal deals
4.1. Introduction
4.2. How to use bigpharma partnering deals
4.3. Bigpharma musculoskeletal partnering company profiles
Abbott
Actavis
Amgen
Astellas
AstraZeneca
Biogen Idec
Bristol-Myers Squibb
Celgene
Daiichi Sankyo
Eisai
Eli Lilly
Endo Pharmaceuticals
Forest Laboratories
GlaxoSmithKline
Hospira
Johnson & Johnson
Menarini
Merck & Co
Merck KGaA
Novartis
Novo Nordisk
Otsuka
Pfizer
Roche
Sanofi
Servier
Shire
Takeda
UCB
Warner Chilcott
Chapter 5 – Musculoskeletal partnering contracts directory
5.1. Introduction
5.2. By deal type
Asset purchase
Assignment
Bigpharma outlicensing
Co-development
Collaborative R&D

5. Co-market
Contract service
Co-promotion
Cross-licensing
Development
Distribution
Equity purchase
Grant
Licensing
Litigation
Loan
Manufacturing
Marketing
Option
Promotion
Research
Royalty financing
Settlement
Sub-license
Supply
Termination
Warranty
5.3. By stage of development
Discovery
Preclinical
Phase I
Phase II
Phase III
Regulatory
Marketed
Formulation
5.4. By technology type
Analysis
Assays
Biological compounds
Biomaterials
Cell therapy
Clinical testing
Devices
Diagnostics
Discovery tools
Drug delivery

6. Enabling technology
Equipment
Facilities
Gene therapy
Genomics
Implant
In vitro models
Natural product
Oligonucleotide
Packaging
Peptides
Processes
Proteomics
Radio/Chemo-therapy
Recombinant DNA
Regenerative medicine
Research services
Research supplies
RNA therapeutics
Screening
Small molecules
Stem cells
Vaccines
Chapter 6 – Musculoskeletal dealmaking by indication
6.1. Introduction
6.2. Deals by therapeutic indication
Musculoskeletal
Arthritis
Osteoarthritis
Psoriatic arthritis
Rheumatoid arthritis
Bone fracture
Hip
Gout
Knee
Muscular dystrophy
Back pain
Bone pain
Muscular pain
Stiffness
Osteoporosis
Paget's disease

7. Spinal muscular atrophy
Chapter 7 – Partnering resource center
7.1. Online partnering
7.2. Partnering events
7.3. Further reading on dealmaking
Appendices
Appendix 1 – Directory of musculoskeletal deals by company A-Z 2007-2012
Appendix 2 – Directory of musculoskeletal deals by deal type 2007-2012
Appendix 3 – Directory of musculoskeletal deals by stage of development 2007-2012
Appendix 4 – Directory of musculoskeletal deals by technology type 2007-2012
Appendix 5 – Deal type definitions
About Wildwood Ventures
Current Partnering
Current Agreements
Recent titles from CurrentPartnering Order Form – Reports
Order Form – Therapy Reports
List of Figures
Figure 1: Musculoskeletal partnering since 2007
Figure 2: Bigpharma – top 50 – musculoskeletal deals 2007 to 2012
Figure 3: Bigpharma musculoskeletal deal frequency – 2007 to 2012
Figure 4: Inactive bigpharma in musculoskeletal 2007-2012
Figure 5: Musculoskeletal partnering by deal type since 2007
Figure 6: Musculoskeletal partnering by industry sector since 2007
Figure 7: Musculoskeletal partnering by stage of development since 2007
Figure 8: Musculoskeletal partnering by technology type since 2007
Figure 9: Musculoskeletal partnering by musculoskeletal target since 2007
Figure 10: Musculoskeletal deals with a headline value
Figure 11: Musculoskeletal deal headline value distribution, US$million – discovery stage
Figure 12: Musculoskeletal deal headline value distribution, US$million – preclinical stage
Figure 13: Musculoskeletal deal headline value distribution, US$million – phase I stage
Figure 14: Musculoskeletal deal headline value distribution, US$million – phase II stage
Figure 15: Musculoskeletal deal headline value distribution, US$million – phase III stage
Figure 16: Musculoskeletal deal headline value distribution, US$million – regulatory stage
Figure 17: Musculoskeletal deal headline value distribution, US$million – marketed stage
Figure 18: Summary median headline value by stage of development, 2007-2012
Figure 19 Musculoskeletal deals with upfront payment values
Figure 20: Musculoskeletal deal upfront payment distribution, US$million – discovery stage
Figure 21: Musculoskeletal deal upfront payment distribution, US$million – preclinical stage
Figure 22: Musculoskeletal deal upfront payment distribution, US$million – phase I stage
Figure 23: Musculoskeletal deal upfront payment distribution, US$million – phase II stage
Figure 24: Musculoskeletal deal upfront payment distribution, US$million – phase III stage
Figure 25: Musculoskeletal deal upfront payment distribution, US$million – regulatory stage

8. Figure 26: Musculoskeletal deal upfront payment distribution, US$million – marketed stage
Figure 27: Summary median upfront payments by stage of development, 2007-2012
Figure 28: Musculoskeletal deals with milestone payments
Figure 29: Musculoskeletal deal milestone distribution, US$million – discovery stage
Figure 30: Musculoskeletal deal milestone distribution, US$million – preclinical stage
Figure 31: Musculoskeletal deal milestone distribution, US$million – phase I stage
Figure 32: Musculoskeletal deal milestone distribution, US$million – phase II stage
Figure 33: Musculoskeletal deal milestone distribution, US$million – phase III stage
Figure 34: Musculoskeletal deal milestone distribution, US$million – regulatory stage
Figure 35: Musculoskeletal deal milestone distribution, US$million – marketed stage
Figure 36: Musculoskeletal deals with royalty rates, %
Figure 37: Musculoskeletal deal royalty rate distribution, US$million – discovery stage
Figure 38: Musculoskeletal deal royalty rate distribution, US$million – preclinical stage
Figure 39: Musculoskeletal deal royalty rate distribution, US$million – phase I stage
Figure 40: Musculoskeletal deal royalty rate distribution, US$million – phase II stage
Figure 41: Musculoskeletal deal royalty rate distribution, US$million – phase III stage
Figure 42: Musculoskeletal deal royalty rate distribution, US$million – regulatory stage
Figure 44: Summary median royalty rate by stage of development, 2007-2012
Figure 45: Top musculoskeletal deals by value since 2007
Figure 46: Top musculoskeletal deals signed by bigpharma value since 2007
Figure 47: Online partnering resources
Figure 48: Forthcoming partnering events
Contact: sales@reportsandreports.com for more information.